Schirmer, Markus A <br/><br/>
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.  [electronic resource] 

 -  Journal of the National Cancer Institute  May 2016 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1460-2105 
<br/><br/><label>Standard No.: </label>10.1093/jnci/djv387  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--genetics<br/>Carcinoma, Pancreatic Ductal--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Resistance, Neoplasm<br/>Electrophoretic Mobility Shift Assay<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Gene Knockdown Techniques<br/>Germ-Line Mutation<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Oxidoreductases--genetics<br/>Pancreatic Neoplasms--drug therapy<br/>Polymorphism, Single Nucleotide<br/>Predictive Value of Tests<br/>Prognosis<br/>Sp Transcription Factors--genetics<br/>Treatment Outcome<br/>Tumor Suppressor Proteins--genetics<br/>WW Domain-Containing Oxidoreductase<br/>Gemcitabine